Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Lifted by Ninety One UK Ltd

Ninety One UK Ltd grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 78,005 shares of the biopharmaceutical company’s stock after buying an additional 9,820 shares during the period. Ninety One UK Ltd’s holdings in Regeneron Pharmaceuticals were worth $55,565,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after acquiring an additional 11,499 shares during the period. Swiss National Bank boosted its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock valued at $316,957,000 after acquiring an additional 3,866 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 4.5 %

Regeneron Pharmaceuticals stock opened at $697.05 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $76.60 billion, a P/E ratio of 17.25, a P/E/G ratio of 1.60 and a beta of 0.08. The company’s fifty day simple moving average is $719.16 and its 200-day simple moving average is $918.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Finally, Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.